<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03571841</url>
  </required_header>
  <id_info>
    <org_study_id>18-140</org_study_id>
    <nct_id>NCT03571841</nct_id>
  </id_info>
  <brief_title>Sexual Health and Rehabilitation After Ovarian Suppression Treatment</brief_title>
  <official_title>Sexual Health and Rehabilitation After Ovarian Suppression Treatment (SHARE-OS): An Educational Intervention for Young Breast Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Howard Cox Fund for Women Assistant Professors</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is evaluating an educational intervention for breast cancer survivors who
      have experienced changes in sexual function after ovarian suppression treatment to reduce the
      risk of breast cancer recurrence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research is to study the effectiveness of an educational intervention for
      breast cancer survivors who have experienced changes in sexual function after ovarian
      suppression treatment to reduce the risk of cancer recurrence. The aim is to develop an
      effective intervention to help women manage these changes and restore sexual health and
      functioning.

      - This study consists of attending a group educational session followed by a one-on-one
      telephone coaching session.

        -  The group educational session will last about 4 hours, and will include information on
           resources, self-help strategies, and relaxation techniques.

        -  The telephone coaching session will take place four weeks after the group session, and
           will last about 15 minutes
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Sexual Function (FSFI)</measure>
    <time_frame>Paired t-test (Wilcoxon signed-rank test) Baseline to 2 Month Follow-up</time_frame>
    <description>Baseline to 2 Month Follow-up Paired t-test (Wilcoxon signed-rank test)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in participants psychological distress on Brief Symptom Inventory</measure>
    <time_frame>Baseline to 2 Months</time_frame>
    <description>Paired t-test (Wilcoxon signed-rank test)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Breast Cancer Survivors</condition>
  <condition>Sexual Function Disturbances</condition>
  <condition>Ovarian Suppression Treatment</condition>
  <arm_group>
    <arm_group_label>Educational Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For breast cancer survivors currently on chemical ovarian suppression who are experiencing sexual dysfunction.
Group Session
Telephone Booster Session</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Group Session</intervention_name>
    <description>The 4-hour group session will be structured around three 60-minute modules and creation of a personal action plan</description>
    <arm_group_label>Educational Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telephone Booster</intervention_name>
    <description>One month following the group session, women will receive a telephone booster session (&lt;15 minutes). This brief telephone check-in is intended to help women review progress with their individualized action-plan, problem-solve around continuing problems, and plan for maintenance moving forward.</description>
    <arm_group_label>Educational Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with a history of breast cancer who are currently on chemical ovarian
             suppression

          -  Current age â‰¤ 50

          -  No active cancer therapy in the past 6 months and no future therapy planned

          -  Endorsement of at least one sexual symptom (see Appendix A for eligibility screening)

          -  English-speaking

        Exclusion Criteria:

          -  History of pelvic radiation

          -  Prior participation in one of Dr. Bober's sexual health workshops
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Bober, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Sharon Bober, Ph.D</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer Survivors</keyword>
  <keyword>Sexual Function Disturbances</keyword>
  <keyword>Ovarian Suppression Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Vision Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

